NCE-1 Intelligence & Market Opportunity

Cobenfy

Xanomeline And Trospium Chloride

Antipsychotic

Oral Capsules

Cobenfy is used to treat schizophrenia. It is the first and only FDA-approved medication for schizophrenia. This drug works by activating muscarinic acetylcholine receptors, which are small proteins in the brain.

Approval Date

26-Sep-24

NCE-1 Date

26-Sep-28

NCE Date

26-Sep-29

Commercial snapshot

Market performance & projections

Revenue ($M)

155

CAGR (%)

0.9334

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

362

2027

817

2028

1419

2029

2166

2030

2920

2031

3618

2032

4321

Molecule profile

Details & specifications

Molecule

Xanomeline And Trospium Chloride

Innovator

BRISTOL-MYERS SQUIBB CO

Dosage Form

Oral Capsules

Strength

50 mg, 100 mg and 125 mg

Therapeutic Category

Antipsychotic

Usage

To treat schizophrenia

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.